Cna Financial Corp Allogene Therapeutics, Inc. Transaction History

Cna Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$13.13 - $24.52 $229,459 - $428,511	-17,476 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $4,307 - $5,666	205 Added 1.19%	17,476 $449,000
Q2 2021 Aug 12, 2021	BUY	$23.49 - $35.8 $53,909 - $82,161	2,295 Added 15.32%	17,271 $450,000
Q1 2021 May 14, 2021	SELL	$25.79 - $39.02 $13,410 - $20,290	-520 Reduced 3.36%	14,976 $529,000
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $105,654 - $181,881	4,186 Added 37.01%	15,496 $391,000
Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $60,226 - $83,625	1,860 Added 19.68%	11,310 $427,000
Q2 2020 Aug 13, 2020	BUY	$18.39 - $54.04 $173,785 - $510,678	9,450 New	9,450 $405,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.